能倍乐气雾剂效果怎么样

Chronic obstructive pulmonary disease (COPD) is a type of chronic bronchitis and/or emphysema characterized by airflow obstruction, which can further develop into common chronic diseases such as cor pulmonale and respiratory failure. It is related to the abnormal inflammatory response of harmful gases and harmful particles, and has a high disability and mortality rate. The global incidence rate for people over 40 years old has been as high as 9% to 10%. Aerosol (Silivar) is a bronchodilator approved by the FDA for the treatment of chronic obstructive pulmonary disease COPD.

Respimat aerosol produces a dilation effect on bronchial smooth muscle by binding to the M3 receptor on smooth muscle. This effect is competitive and reversible. In vivo and in vitro studies have shown that Respimat has a dose-dependent and sustainable 24-hour inhibition of methacholine-induced bronchoconstriction. Respimat's bronchial dilation effect has outstanding localization selectivity.

How effective is Respimat aerosol?

The approval of Respimat was based on data from two pivotal Phase III trials (TONADO-1, -2). The study involved more than 5,000 COPD patients. Data showed that compared with placebo, tiotropium bromide, and olodaterol monotherapy, Respimat produced a statistically significant improvement in patients' lung function (FEV1) and had a similar safety profile to tiotropium bromide or olodaterol.

Respimat Aerosol (Spirax) helps open the airways, making it easier for air to move in and out of the lungs. Normal use of Respimat can also relieve persistent shortness of breath caused by the disease, helping to minimize the impact of the disease on daily life.

The above is an introduction to the therapeutic effects of aerosol. If you need to purchase this medicine, please consult the Medical Companion Travel Service for the specific price and purchase method.

Recommended related hot articles: /newsDetail/82345.html